nach oben

Erschienen in:

08.08.2020 | Letter to the Editor

Letter to the Editor-Recent advances in Lynch syndrome

verfasst von: Pål Møller, Julian Sampson, Mev Dominguez-Valentin, John Burn, Lone Sunde, Gabriela Möslein, Jukka-Pekka Mecklin, Toni Seppälä

Erschienen in: Familial Cancer | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Excerpt

In April 2019, Familial Cancer published an article ‘Recent advances in Lynch Syndrome’ by Biller, Syngal and Yurgelun [1]. Unfortunately, their review contained misunderstandings of some of the sources they cite, among which reports from the Prospective Lynch Syndrome Database (PLSD). …

Biller LH, Syngal S, Yurgelun MB (2019) Recent advances in Lynch syndrome. Familial Cancer 18:211. https://doi.org/10.1007/s10689-018-00117-1CrossRefPubMedPubMedCentral

Engel C, Vasen HF, Seppala T et al (2018) No difference in colorectal cancer incidence or stage at detection by colonoscopy among 3 countries with different Lynch syndrome surveillance policies. Gastroenterology. https://doi.org/10.1053/j.gastro.2018.07.030CrossRefPubMed

Møller P, Seppälä T, Bernstein I et al (2017) Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the Prospective Lynch Syndrome Database. Gut 66(3):464–472. https://doi.org/10.1136/gutjnl-2015-309675CrossRefPubMed

Moller P, Seppala T, Bernstein I et al (2017) Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the Prospective Lynch Syndrome Database. Gut 66(9):1657–1664. https://doi.org/10.1136/gutjnl-2016-311403CrossRefPubMed

Møller P, Seppälä TT, Bernstein I et al (2018) Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut 67(7):1306CrossRefPubMed

Møller P (2020) The prospective Lynch syndrome database reports enable evidence-based personal precision health care. Hered Cancer Clin Pract 8:6. https://doi.org/10.1186/s13053-020-0138-0CrossRef

Seppälä TT, Dominguez-Valentin M, Sampson JR, Møller P (2020) Prospective observational data informs understanding and future management of Lynch syndrome: insights from the Prospective Lynch Syndrome Database (PLSD). Fam Cancer. https://doi.org/10.1007/s10689-020-00193-2CrossRefPubMedPubMedCentral

Titel: Letter to the Editor-Recent advances in Lynch syndrome
verfasst von: Pål Møller
Julian Sampson
Mev Dominguez-Valentin
John Burn
Lone Sunde
Gabriela Möslein
Jukka-Pekka Mecklin
Toni Seppälä
Publikationsdatum: 08.08.2020
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 2/2021
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-020-00200-6

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Letter to the Editor-Recent advances in Lynch syndrome

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Is a colorectal neoplasm diagnosis a trigger to change dietary and other lifestyle habits for persons with Lynch syndrome? A prospective cohort study

Quantitative evaluation of MSI testing using NGS detects the imperceptible microsatellite changed caused by MSH6 deficiency

Correction to: Letter to the Editor—Recent advances in Lynch syndrome: response to Møller et al.

Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants

Patient reported experiences following laparoscopic prophylactic bilateral salpingo-oophorectomy or salpingectomy in an ambulatory care hospital

Clinical phenotypes combined with saturation genome editing identifying the pathogenicity of BRCA1 variants of uncertain significance in breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie